Celltrion Healthcare: New Data Show Statistically Greater Im

Presented today at EULAR 2022, data from a new post-hoc analysis show a statistically significant difference in clinical outcomes with subcutaneous (SC) infliximab compared to intravenous (IV) infliximab

Related Keywords

Japan , United States , Canada , United Kingdom , France , American , Kostenloser Wertpapierhandel , Arnaud Constantin , Donna Curran , Kevin Byoung Seo Choi , Allan Gibofsky , Arthritis Research United Kingdom , European Congress , Rheumatologist At Rheumatology Department , European Commission , Drug Administration , Celltrion Inc , Head Of Marketing Division At Celltrion Healthcare , Paul Sabatier University , Purpan University Hospital , Arthritis Foundation , Annual European Congress , Professor Arnaud Constantin , Rheumatology Department , Sabatier University , Senior Vice President , Marketing Division , Rheumatoid Arthritis , Inflammatory Bowel Disease , Good Manufacturing Practice , Subcutaneous Infliximab , Intravenous Infliximab , Post Hoc Analysis , Research United , American Journal , Treatment Available , Medicines Agency Summary , Product Characteristics , Novel Formulation , Celltrion , Healthcare , Data , Show , Statistically , Greater , Improvements , Linical , Outcomes , Subcutaneous , Infliximab , Ompared , Intravenous , Patients , Ith , Rheumatoid , Arthritis ,